Division of Neuroscience, Department of Pharmacology, Shrimati Kishoritai Bhoyar College of Pharmacy, New Kamptee, Nagpur, Maharashtra, India.
Br J Pharmacol. 2011 Sep;164(2b):704-18. doi: 10.1111/j.1476-5381.2011.01484.x.
Agmatine, a multifaceted neurotransmitter, is abundantly expressed in the hypothalamic paraventricular nucleus (PVN). Our aim was to assess (i) the effect of agmatine on feeding behaviour and (ii) its association, if any, with neuropeptide Y (NPY).
Satiated rats fitted with intra-PVN cannulae were administered agmatine, alone or jointly with (i) α₂-adrenoceptor agonist, clonidine, or antagonist, yohimbine; (ii) NPY, NPY Y₁ receptor agonist, [Leu³¹, Pro³⁴]-NPY, or antagonist, BIBP3226; or (iii) yohimbine and NPY. Cumulative food intake was monitored at different post-injection time points. Furthermore, the expression of hypothalamic NPY following i.p. treatment with agmatine, alone or in combination with yohimbine (i.p.), was evaluated by immunocytochemistry.
Agmatine robustly increased feeding in a dose-dependent manner. While pretreatment with clonidine augmented, yohimbine attenuated the orexigenic response to agmatine. Similarly, NPY and [Leu³¹, Pro³⁴]-NPY potentiated the agmatine-induced hyperphagia, whereas BIBP3226 inhibited it. Moreover, yohimbine attenuated the synergistic orexigenic effect induced by the combination of NPY and agmatine. Agmatine increased NPY immunoreactivity in the PVN fibres and in the cells of the hypothalamic arcuate nucleus (ARC) and this effect was prevented by pretreatment with yohimbine. NPY immunoreactivity in the fibres of the ARC, dorsomedial, ventromedial and lateral nuclei of the hypothalamus was not affected by any of the above treatments.
The orexigenic effect of agmatine is coupled to increased NPY activity mediated by stimulation of α₂-adrenoceptors within the PVN. This signifies the importance of agmatine or α₂-adrenoceptor modulators in the development of novel therapeutic agents to treat feeding-related disorders.
胍丁胺是一种多功能神经递质,在下丘脑室旁核(PVN)中大量表达。我们的目的是评估(i)胍丁胺对摄食行为的影响,以及(ii)它与神经肽 Y(NPY)的任何关联。
给 PVN 腔内装有导管的饱食大鼠单独或联合给予胍丁胺、(i)α₂-肾上腺素受体激动剂可乐定或拮抗剂育亨宾;(ii)NPY、NPY Y₁受体激动剂[Leu³¹,Pro³⁴]-NPY 或拮抗剂 BIBP3226;或(iii)育亨宾和 NPY。在不同的注射后时间点监测累积食物摄入量。此外,通过免疫细胞化学评估腹腔内给予胍丁胺单独或与育亨宾(腹腔内)联合处理后下丘脑 NPY 的表达。
胍丁胺以剂量依赖的方式强烈增加摄食。虽然可乐定预处理增强了,但育亨宾减弱了胍丁胺引起的食欲反应。同样,NPY 和 [Leu³¹,Pro³⁴]-NPY 增强了胍丁胺引起的多食,而 BIBP3226 抑制了它。此外,育亨宾减弱了 NPY 和胍丁胺联合引起的协同食欲作用。胍丁胺增加了 PVN 纤维和下丘脑弓状核(ARC)细胞中的 NPY 免疫反应,而育亨宾预处理可防止这种作用。ARC 纤维、下丘脑背内侧核、腹内侧核和外侧核中的 NPY 免疫反应不受上述任何处理的影响。
胍丁胺的食欲作用与刺激 PVN 内的α₂-肾上腺素受体而增加 NPY 活性有关。这表明胍丁胺或α₂-肾上腺素受体调节剂在开发治疗摄食相关疾病的新型治疗药物方面具有重要意义。